Iron deficiency is the most common cause of anemia worldwide and can significantly impact growth, energy levels, and overall well-being—especially in children and adolescents. While over-the-counter iron supplements are widely available, standardized prescription treatment options for pediatric patients have been limited.
The U.S. Food and Drug Administration has approved Ferric maltol (Accrufer) capsules for the treatment of iron deficiency in patients aged 10 years and older. The drug was previously approved in 2019 for adults and is now expanded to include pediatric use.
Table of Contents
- Introduction to Ferric Maltol and Mechanism of Action
- Understanding Iron Deficiency
- Clinical Trial Evidence (FORTIS Study)
- Dosage and Administration
- Safety Information and Adverse Events
- Conclusion and Future Perspectives
- Frequently Asked Questions (FAQs)
1. Introduction to Ferric Maltol and Mechanism of Action
Ferric maltol (Accrufer) is an oral iron replacement therapy designed to improve iron absorption in the gastrointestinal tract. It helps restore iron stores and supports the production of hemoglobin, the protein responsible for oxygen transport in red blood cells.
2. Understanding Iron Deficiency
Iron deficiency occurs when the body does not have enough iron to produce adequate hemoglobin.
Common Symptoms:
- Fatigue
- Pale skin
- Dizziness
Common Causes:
- Blood loss (especially gastrointestinal)
- Menstruation
- Malabsorption
- Low dietary iron intake
3. Clinical Trial Evidence
FORTIS Study (NCT05126901)
The efficacy of Accrufer was evaluated in pediatric patients aged 10–17 years.
- Total patients: 24
- Treatment: Twice daily dosing
Key Result:
- Mean hemoglobin increase: 1.1 g/dL at Week 12
This increase is approximately equivalent to the expected hemoglobin rise from a single blood transfusion.
4. Dosage and Administration
- Recommended use: Oral, twice daily
- Dosing: Adjusted based on patient age
- Can be taken with or without food
5. Safety Information and Adverse Events
Contraindications:
Patients should not use Accrufer if they:
- Are allergic to ferric maltol or its components
- Have iron overload conditions (e.g., hemochromatosis)
- Receive repeated blood transfusions
Warnings:
- Avoid use during inflammatory bowel disease (IBD) flare-ups
- Monitor for risk of iron overload
Common Side Effects:
- Flatulence
- Diarrhea
- Constipation
- Discolored feces
- Abdominal pain
- Nausea and vomiting
- Abdominal discomfort or bloating
6. Conclusion and Future Perspectives
The approval of Ferric maltol (Accrufer) for pediatric patients represents a meaningful advancement in the management of iron deficiency. As a prescription oral therapy, it offers a more controlled and clinically validated alternative to traditional iron supplements.
From a clinical standpoint, the demonstrated increase in hemoglobin levels within a relatively short timeframe highlights its effectiveness and potential to reduce the need for more invasive interventions such as blood transfusions in certain cases.
However, careful patient selection and monitoring remain essential, particularly regarding the risk of iron overload and appropriate use in patients with underlying conditions. Future large-scale and real-world studies will be important to further define its long-term safety and role in treatment guidelines.
Overall, Accrufer provides a practical and effective option that may improve treatment outcomes and quality of life for pediatric patients with iron deficiency.
7. Frequently Asked Questions (FAQs)
- Who is eligible for Accrufer treatment?
Patients aged 10 years and older with iron deficiency. - How is Accrufer different from iron supplements?
It is a prescription medication with clinically proven efficacy, not just a dietary supplement. - What is its effectiveness?
An average hemoglobin increase of 1.1 g/dL within 12 weeks. - What are the most common side effects?
Gastrointestinal symptoms such as bloating, diarrhea, and nausea. - Who should avoid taking it?
Patients with iron overload disorders or hypersensitivity to the drug.
